Condition: Rheumatoid Arthritis (RA) · Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
The purpose of the study is to evaluate the safety and efficacy of BCMAxCD3 T-cell engager (cizutamig) in patients with refractory seropositive RA.
This description comes directly from the study's public registry record.
Qiubai Li, Professor · 85726808 · qiubaili@hust.edu.cn
Di Wu · 18790696175 · 373181302@qq.com
Always discuss trial participation with your own doctor first.
| Wuhan Union Hospital | Wuhan, Hubei, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06946199